These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 23706326

  • 1. Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program.
    Widimsky P, Motovska Z, Belardi J, Serruys P, Silber S, Windecker S, Neumann FJ.
    Int J Cardiol; 2013 Oct 09; 168(4):3522-6. PubMed ID: 23706326
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P, RESOLUTE All Comers, RESOLUTE International Investigators.
    JACC Cardiovasc Interv; 2013 Sep 09; 6(9):905-13. PubMed ID: 23954063
    [Abstract] [Full Text] [Related]

  • 3. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S, RESOLUTE All-Comers Investigators.
    J Am Coll Cardiol; 2014 Apr 29; 63(16):1617-25. PubMed ID: 24530680
    [Abstract] [Full Text] [Related]

  • 4. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F.
    Circ Cardiovasc Interv; 2013 Aug 29; 6(4):378-90. PubMed ID: 23922145
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.
    Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW.
    J Am Coll Cardiol; 2013 Aug 06; 62(6):496-504. PubMed ID: 23747778
    [Abstract] [Full Text] [Related]

  • 6. Outcome of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with titanium-nitride-oxide-coated versus everolimus-eluting stents: insights from the BASE-ACS trial.
    Romppanen H, Nammas W, Kervinen K, Mikkelsson J, Pietilä M, Lalmand J, Rivero-Crespo F, Pentikäinen M, Tedjokusumo P, Karjalainen PP.
    Minerva Cardioangiol; 2013 Apr 06; 61(2):201-9. PubMed ID: 23492603
    [Abstract] [Full Text] [Related]

  • 7. Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction.
    Park KW, Lim WH, Kim JH, Kang SH, Seo JW, Song YB, Hahn JY, Lee HY, Kang HJ, Cho YS, Youn TJ, Koo BK, Choi SH, Chae IH, Gwon HC, Choi DJ, Kim HS.
    Int J Cardiol; 2013 Jun 05; 166(1):118-25. PubMed ID: 22062892
    [Abstract] [Full Text] [Related]

  • 8. Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial.
    Postma W, Fabris E, Van der Ent M, Hermanides R, Buszman P, Von Birgelen C C, Cook S, Wedel H, De Luca G, Delewi R, Zijlstra F, Kedhi E.
    Catheter Cardiovasc Interv; 2020 Mar 01; 95(4):706-710. PubMed ID: 31268629
    [Abstract] [Full Text] [Related]

  • 9. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.
    Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R.
    JAMA Cardiol; 2017 Aug 01; 2(8):855-862. PubMed ID: 28658478
    [Abstract] [Full Text] [Related]

  • 10. Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy.
    Thim T, Maeng M, Kaltoft A, Jensen LO, Tilsted HH, Hansen PR, Kelbaek H, Thayssen P, Ravkilde J, Madsen M, Sørensen HT, Thuesen L, Lassen JF.
    Eur J Clin Invest; 2012 Oct 01; 42(10):1047-54. PubMed ID: 22624990
    [Abstract] [Full Text] [Related]

  • 11. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
    Colleran R, Kufner S, Harada Y, Giacoppo D, Cassese S, Repp J, Wiebe J, Lohaus R, Lahmann A, Schneider S, Ibrahim T, Laugwitz KL, Kastrati A, Byrne RA, Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Investigators.
    Catheter Cardiovasc Interv; 2017 Feb 15; 89(3):367-374. PubMed ID: 27377301
    [Abstract] [Full Text] [Related]

  • 12. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K.
    Lancet; 2014 Feb 01; 383(9915):413-23. PubMed ID: 24183564
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH.
    J Am Coll Cardiol; 2012 Apr 10; 59(15):1350-61. PubMed ID: 22341737
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program.
    Di Mario C, Serruys PW, Silber S, Lu S, Wang W, Widimský P, Xu B, Windecker S.
    EuroIntervention; 2016 Nov 20; 12(10):1207-1214. PubMed ID: 27866129
    [Abstract] [Full Text] [Related]

  • 16. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.
    Circulation; 2012 Jun 12; 125(23):2873-91. PubMed ID: 22586281
    [Abstract] [Full Text] [Related]

  • 17. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
    Rozemeijer R, Stein M, Voskuil M, van den Bor R, Frambach P, Pereira B, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Agostoni P, Roes KC, Doevendans PA, Stella PR, ReCre8 Study Investigators.
    Circulation; 2019 Jan 02; 139(1):67-77. PubMed ID: 30586704
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry).
    Dvir D, Barbash IM, Torguson R, Badr S, Sardi GL, Laynez-Carnicero A, Ben-Dor I, Satler LF, Pichard AD, Waksman R.
    Cardiovasc Revasc Med; 2013 Jan 02; 14(3):128-33. PubMed ID: 23642502
    [Abstract] [Full Text] [Related]

  • 19. Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents.
    Leibundgut G, Nietlispach F, Pittl U, Brunner-La Rocca H, Kaiser CA, Pfisterer ME.
    Am Heart J; 2009 Aug 02; 158(2):271-6. PubMed ID: 19619705
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH, Fang Q, Zhang SY, Shen ZJ, Fan ZJ, Jin XF, Zeng Y, Liu ZY, Xie HZ, Yang M.
    Chin Med J (Engl); 2012 Aug 02; 125(16):2803-6. PubMed ID: 22932070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.